
Belatacept injection
Form: Injection
Strength: 250 mg/vial
Reference Brands: Nulojix(US)
Category: Transplant
Belatacept, marketed as Nulojix, is approved in the US by the FDA and in the EU via EMA for rejection prevention in adult kidney transplant recipients. Regulatory approval requires comprehensive dossiers, including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality information, while the EMA ensures compliance with regional safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Ensuring proper regional adherence supports timely approval, safe use, and global availability, helping transplant patients achieve optimal long-term outcomes and graft survival worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Cotrimoxazole tablets
Strength: 80 mg trimethoprim / 400 mg sulfamethoxazole
Form: Tablets
Reference Brands: Bactrim, Septra(US & EU)
View Details Get EnquiryAcyclovir tablet
Strength: 200 mg, 400 mg, 800 mg
Form: Tablets
Reference Brands: Zovirax(US & EU)
View Details Get EnquiryBasiliximab Injectable Solution
Strength: 20 mg/vial
Form: Injectable Solution
Reference Brands: Simulect(US)
View Details Get EnquiryPrednisolone syrup
Strength: 15 mg/5ml
Form: Syrup
Reference Brands: Orapred(US)
View Details Get Enquiry